- Home
- MNRO vs SRRK Comparison
MNRO vs SRRK Comparison
Compare MNRO & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNRO
- SRRK
- Stock Information
- Founded
- MNRO 1957
- SRRK 2012
- Country
- MNRO United States
- SRRK United States
- Employees
- MNRO N/A
- SRRK N/A
- Industry
- MNRO Automotive Aftermarket
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNRO Consumer Discretionary
- SRRK Health Care
- Exchange
- MNRO Nasdaq
- SRRK Nasdaq
- Market Cap
- MNRO 822.2M
- SRRK 619.7M
- IPO Year
- MNRO 1991
- SRRK 2018
- Fundamental
- Price
- MNRO $25.28
- SRRK $8.03
- Analyst Decision
- MNRO
- SRRK Strong Buy
- Analyst Count
- MNRO 0
- SRRK 6
- Target Price
- MNRO N/A
- SRRK $27.00
- AVG Volume (30 Days)
- MNRO 364.6K
- SRRK 578.2K
- Earning Date
- MNRO 10-23-2024
- SRRK 08-08-2024
- Dividend Yield
- MNRO 4.43%
- SRRK N/A
- EPS Growth
- MNRO N/A
- SRRK N/A
- EPS
- MNRO 1.09
- SRRK N/A
- Revenue
- MNRO $1,243,003,000.00
- SRRK N/A
- Revenue This Year
- MNRO N/A
- SRRK N/A
- Revenue Next Year
- MNRO $3.34
- SRRK N/A
- P/E Ratio
- MNRO $23.21
- SRRK N/A
- Revenue Growth
- MNRO N/A
- SRRK N/A
- 52 Week Low
- MNRO $21.00
- SRRK $5.94
- 52 Week High
- MNRO $33.98
- SRRK $21.17
- Technical
- Relative Strength Index (RSI)
- MNRO 42.55
- SRRK 34.71
- Support Level
- MNRO $26.28
- SRRK $8.69
- Resistance Level
- MNRO $27.42
- SRRK $9.59
- Average True Range (ATR)
- MNRO 0.73
- SRRK 0.56
- MACD
- MNRO -0.25
- SRRK -0.11
- Stochastic Oscillator
- MNRO 21.79
- SRRK 4.60
About MNRO Monro Inc.
Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.